DK3453721T3 - Process of manufacture of annexin v - Google Patents

Process of manufacture of annexin v Download PDF

Info

Publication number
DK3453721T3
DK3453721T3 DK18182321.2T DK18182321T DK3453721T3 DK 3453721 T3 DK3453721 T3 DK 3453721T3 DK 18182321 T DK18182321 T DK 18182321T DK 3453721 T3 DK3453721 T3 DK 3453721T3
Authority
DK
Denmark
Prior art keywords
annexin
manufacture
Prior art date
Application number
DK18182321.2T
Other languages
English (en)
Inventor
Toomas Moks
Jan Christoph Reich
Original Assignee
Annexin Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annexin Pharmaceuticals Ab filed Critical Annexin Pharmaceuticals Ab
Application granted granted Critical
Publication of DK3453721T3 publication Critical patent/DK3453721T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
DK18182321.2T 2015-09-17 2016-09-16 Process of manufacture of annexin v DK3453721T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1516516.0A GB2542391A (en) 2015-09-17 2015-09-17 Process of manufacture
EP16766559.5A EP3283506B1 (en) 2015-09-17 2016-09-16 Process of manufacture of annexin v

Publications (1)

Publication Number Publication Date
DK3453721T3 true DK3453721T3 (da) 2022-06-07

Family

ID=54544424

Family Applications (2)

Application Number Title Priority Date Filing Date
DK18182321.2T DK3453721T3 (da) 2015-09-17 2016-09-16 Process of manufacture of annexin v
DK16766559.5T DK3283506T3 (da) 2015-09-17 2016-09-16 Fremgangsmåde til fremstilling af annexin v

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK16766559.5T DK3283506T3 (da) 2015-09-17 2016-09-16 Fremgangsmåde til fremstilling af annexin v

Country Status (11)

Country Link
US (3) US11773134B2 (da)
EP (3) EP3283506B1 (da)
JP (4) JP6689371B2 (da)
CN (3) CN116333031A (da)
CA (2) CA3193026A1 (da)
DK (2) DK3453721T3 (da)
ES (2) ES2699155T3 (da)
GB (1) GB2542391A (da)
HK (1) HK1251580B (da)
PL (2) PL3453721T3 (da)
WO (1) WO2017046391A2 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3495376A1 (en) * 2017-12-05 2019-06-12 ChromaCon AG Improved chromatographic process for cell culture harvest
EP3560945A1 (en) * 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Methods for purification of polypeptides using polysorbates
EP3845548A4 (en) * 2018-08-31 2022-05-25 Kaneka Corporation METHOD OF PURIFYING AN ANTIBODY OR ANTIBODY-LIKE MOLECULE
CN110669141A (zh) * 2019-09-29 2020-01-10 杭州联科生物技术股份有限公司 一种别藻蓝蛋白(APC)与Annexin V蛋白偶联方法
TW202146042A (zh) * 2020-03-06 2021-12-16 瑞典商阿斯特捷利康公司 用於治療動脈和靜脈血栓形成的協同且靶向的組成物
CN111378005B (zh) * 2020-04-03 2021-08-17 安徽环球基因科技有限公司 一种可调式纯化蛋白装置
WO2023104874A2 (en) * 2021-12-08 2023-06-15 Ferring B.V. Method
CN114539383B (zh) * 2022-02-24 2024-03-26 南京大学 一种人源膜联蛋白人源膜联蛋白a5突变体二聚体的晶体结构的制备方法和应用
GB202207263D0 (en) * 2022-05-18 2022-06-29 Annexin Pharmaceuticals Ab Therapeutic compositions

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU601676B2 (en) * 1985-01-10 1990-09-20 Biogen, Inc. Dna sequences recombinant dna molecules and processes for producing human lipocorton-like polypeptides
DE3643182A1 (de) 1986-12-18 1988-06-30 Behringwerke Ag Arzneimittel enthaltend das gewebeprotein pp4, verfahren zur herstellung von pp4 und zu seiner pasteurisierung sowie die verwendung von pp4
DE3939169A1 (de) 1989-11-27 1991-05-29 Behringwerke Ag Verfahren zur reinigung von lipocortinen
DE4003773A1 (de) 1990-02-08 1991-08-14 Behringwerke Ag Verfahren zur reinigung von lipocortinen
DE4012341A1 (de) 1990-04-18 1991-10-24 Behringwerke Ag Monoklonale antikoerper gegen pp4, verfahren zu ihrer herstellung und ihre verwendung
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
JP2000239299A (ja) 1999-02-15 2000-09-05 Snow Brand Milk Prod Co Ltd 新規蛋白質及びその製造方法
US6492327B2 (en) * 2000-12-19 2002-12-10 Sulzer Biologics Inc. Isolation of purified TGF- β1 and TGF -β2 from bone tissue
GB0101300D0 (en) * 2001-01-18 2001-02-28 Univ Cambridge Tech Primordial germ cell genes
US7635680B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
EP1839670A3 (en) 2001-02-21 2009-11-11 Alavita Pharmaceuticals, Inc. Modified Annexin Proteins and their use against thrombosis
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
EP1389090A2 (en) * 2001-04-26 2004-02-18 Board of Regents, The University of Texas System Diagnostic imaging compositions, their methods of synthesis and use
US6825027B2 (en) * 2001-12-10 2004-11-30 Baxter Healthcare S.A. Method of production of purified hepatitis a virus particles and vaccine preparation
CH696701A5 (de) * 2001-12-18 2007-10-15 Hoffmann La Roche Verfahren zum Testen eines Mittels auf dessen Fähigkeit, die Heparanaseaktivität zu hemmen.
US7148049B2 (en) * 2002-04-02 2006-12-12 Roche Molecular Systems, Inc. Thermostable or thermoactive DNA polymerase molecules with attenuated 3′-5′ exonuclease activity
TW200504218A (en) * 2003-03-04 2005-02-01 Smithkline Beecham Corp Methods for preventing gluconoylation of proteins
AU2005221195B2 (en) 2004-03-11 2011-05-19 Alavita Pharmaceuticals, Inc. Modified annexin proteins and methods for preventing thrombosis
ES2356364T3 (es) * 2004-04-15 2011-04-07 Athera Biotechnologies Ab Anexina v para prevenir la ruptura de la placa.
WO2006014477A1 (en) * 2004-07-06 2006-02-09 Bioren, Inc. HIGH AFFINITY ANTI-TNF-α ANTIBODIES AND METHOD
US7511016B2 (en) * 2004-07-07 2009-03-31 Mosamedix B.V. Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
WO2006081320A2 (en) * 2005-01-27 2006-08-03 Human Genome Sciences, Inc. Pharmaceutical formulation
PL2234631T3 (pl) * 2007-12-18 2013-03-29 Athera Biotechnologies Ab Związki i metody stosowane w terapii choroby naczyniowej
GB0905348D0 (en) 2009-03-27 2009-05-13 Ucl Business Plc Carrier
ES2630013T3 (es) * 2008-02-22 2017-08-17 Annexin Pharmaceuticals Ab Compuestos y procedimientos para la prevención o tratamiento de reestenosis
ITCZ20080004A1 (it) * 2008-02-26 2009-08-27 Univ Bari Anticorpo monospecifico e metodo di produzione mediante l utilizzo come antigene di un isoforma della fad sintetasi umana
WO2010043232A1 (en) * 2008-10-17 2010-04-22 Tallinn University Of Technology Potato virus a coat protein-based vaccine for treating melanoma and its use
JP5590621B2 (ja) 2008-10-17 2014-09-17 ロンドン ヘルス サイエンシーズ センター リサーチ インコーポレイテッド 炎症性障害の処置を処置するためのアネキシンおよびその使用
EP2380023A2 (en) * 2008-12-19 2011-10-26 Medirista Biotechnologies AB Oxidized cardiolipin as a novel pro-inflammatory factor
JP2012528855A (ja) * 2009-06-03 2012-11-15 モサメディックス・ビー．ブイ． ホスファチジルセリン露出細胞の食作用を向上させるための方法
WO2011051916A2 (en) * 2009-11-02 2011-05-05 Universite De Geneve Stabilized protein formulations and use thereof
AU2011247567B2 (en) * 2010-04-29 2014-06-19 Takeda Pharmaceutical Company Limited Purification method for divalent cation binding proteins on anion exchange resin
BR112012029611A2 (pt) * 2010-05-21 2017-07-25 Merrimack Pharmaceuticals Inc proteína de fusão biespecífica, composição farmacêutica, método de tratamento de dano ao tecido em um indivíduo, método de promoção da regeração ou sobrevivência do tecido em um indivíduo e molécula de ácido nucleico
CN102690345B (zh) 2011-03-24 2014-03-19 江苏靶标生物医药研究所有限公司 人膜联蛋白v变体及其表达、制备和应用
PL2694538T3 (pl) * 2011-04-05 2017-04-28 Annexin Pharmaceuticals Ab Sposoby terapeutyczne i profilaktyczne, zastosowania i kompozycje zawierające aneksynę a5
US9701710B2 (en) * 2011-10-14 2017-07-11 Baxalta Incorporated Protein purification by anion exchange chromatography
JP6290187B2 (ja) 2012-05-11 2018-03-07 クランツ，アレクサンダー 癌の処置のためのタンパク質の部位特異的標識及び標的送達
JP6355641B2 (ja) * 2012-11-05 2018-07-11 ファイザー・インク スプライソスタチン類似体
AU2013360812B2 (en) * 2012-12-21 2018-11-08 Ichnos Sciences SA Anti HER2 antibody formulation
WO2016115431A1 (en) * 2015-01-16 2016-07-21 The Johns Hopkins University Methods for enhancing antigen-specific immune responses

Also Published As

Publication number Publication date
CN116333087A (zh) 2023-06-27
GB2542391A (en) 2017-03-22
CA3036298A1 (en) 2017-03-23
PL3453721T3 (pl) 2022-11-07
RU2018113265A (ru) 2019-10-17
JP2021176856A (ja) 2021-11-11
CN108137662A (zh) 2018-06-08
EP3283506B1 (en) 2018-08-29
PL3283506T3 (pl) 2019-02-28
GB201516516D0 (en) 2015-11-04
RU2018113265A3 (da) 2019-10-17
JP2023088961A (ja) 2023-06-27
JP2018534250A (ja) 2018-11-22
US20240116982A1 (en) 2024-04-11
WO2017046391A2 (en) 2017-03-23
EP3453721B1 (en) 2022-05-25
EP3453721A1 (en) 2019-03-13
ES2699155T3 (es) 2019-02-07
ES2920156T3 (es) 2022-08-01
CA3193026A1 (en) 2017-03-23
US20200262866A1 (en) 2020-08-20
JP2020040951A (ja) 2020-03-19
US20210347819A1 (en) 2021-11-11
DK3283506T3 (da) 2018-12-03
US11472837B2 (en) 2022-10-18
JP6910408B2 (ja) 2021-07-28
CN108137662B (zh) 2022-08-30
EP3283506A2 (en) 2018-02-21
EP4134376A1 (en) 2023-02-15
HK1251580B (zh) 2019-10-18
WO2017046391A3 (en) 2017-06-08
US11773134B2 (en) 2023-10-03
JP6689371B2 (ja) 2020-04-28
CN116333031A (zh) 2023-06-27

Similar Documents

Publication Publication Date Title
DK3453721T3 (da) Process of manufacture of annexin v
DK3341479T3 (da) LNA-G-Proces
DK3237432T3 (da) Proteinfremstilling
DK3283210T3 (da) Fremgangsmåde
DK3132009T3 (da) Fremgangsmåde
GB2522719B (en) Method of manufacture
GB201518792D0 (en) Production of proteins
IL252712A0 (en) Method for protein production
GB201609170D0 (en) Method of manufacture
GB2522716B (en) Method of manufacture
KR20180084828A (ko) 신장된 요소의 검사 그룹
DK3285588T3 (da) Fremgangsmåde
GB201613971D0 (en) Method of manufacture
GB201609171D0 (en) Method of manufacture
FI20155387A (fi) Sterolien tuottaminen
FR3024647B1 (fr) Transat de puericulture
FR3019594B1 (fr) Section additionnelle de poussee
ES1101930Y (es) Pulsera portagomas
GB201700973D0 (en) Process of manufacture
IL263300A (en) METHODS FOR THE PRODUCTION OF CERTAIN CONVERSIONED SULPLAYIMINS
IT201600129753A1 (it) Struttura di calcio-balilla
SMP201500137B1 (it) Metodo di produzione
UA32007S (uk) Елемент ювелірного виробу
UA32008S (uk) Елемент ювелірного виробу
GB201700978D0 (en) Process of manufacture